Stay updated on Anti-PD1 Combo with Tisagenlecleucel in ALL Clinical Trial
Sign up to get notified when there's something new on the Anti-PD1 Combo with Tisagenlecleucel in ALL Clinical Trial page.

Latest updates to the Anti-PD1 Combo with Tisagenlecleucel in ALL Clinical Trial page
- Check6 days agoChange DetectedThe Study Record Versions list adds revision v3.5.2 and removes revision v3.5.0.SummaryDifference0.1%

- Check14 days agoNo Change Detected
- Check21 days agoNo Change Detected
- Check28 days agoChange DetectedRevision history updated with a new entry (v3.5.0) and removal of an older entry (v3.4.3).SummaryDifference0.1%

- Check42 days agoChange DetectedA new revision entry (v3.4.3) was added and the previous revision (v3.4.2) removed in the study record history. This indicates a minor site release rather than substantive changes to study information.SummaryDifference0.1%

- Check71 days agoChange DetectedRevision history now shows a new entry for v3.4.2 and removal of a funding notice; these are administrative updates that do not alter study details or content. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check78 days agoChange DetectedAdministrative updates include a new government funding notice and the addition of Revision: v3.4.1 with Revision: v3.4.0 removed on the history page; these changes do not affect the study data or the page’s core purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.9%

- Check85 days agoChange DetectedUI and text updates include a new 'Show glossary' option, color-coded change indicators, and a revision label updated to v3.4.0, with capitalization adjusted for 'No FEAR Act Data'. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference1%

Stay in the know with updates to Anti-PD1 Combo with Tisagenlecleucel in ALL Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Anti-PD1 Combo with Tisagenlecleucel in ALL Clinical Trial page.